hepatitis B

Children vaccinated against hepatitis B not at increased risk of MS

harminka — Fri, 26 Sep 2008 07:11:27 -0500

The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS), according to a study to be published in the October 8, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.

How to select anti-hepatitis B virus agents for drug-resistance patients?

harminka — Wed, 24 Sep 2008 11:22:17 -0500

HBV infection may lead to acute liver disease, chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma. Over 350 million people worldwide are estimated to be infected chronically by HBV and are therefore at risk of liver failure, cirrhosis, or hepatocellular carcinoma.

Safer, more efficient medication for hepatitis B treatment

harminka — Fri, 27 Jun 2008 08:02:38 -0500

Patients with hepatitis B who did not respond to lamivudine therapy had a better virological response after switching to entecavir for a year. Continuing the drug for an additional year led to even more clinical improvement without significant side effects, according to a new study in the July issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Progression of hepatitis B disease

harminka — Wed, 30 Apr 2008 14:58:26 -0500

Genotype D is found to be the only detected type in different clinical forms of HBV infections, including cirrhosis, among residents of southwestern Iran. A significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals was also determined.

Low resistance over 5 years in nucleoside-naive hepatitis B patients

harminka — Tue, 25 Mar 2008 13:51:54 -0500

New BARACLUDE (entecavir) data presented today demonstrated a continued low incidence of resistance in nucleoside-naпve patients through five years of treatment. In the nucleoside-naпve chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108).

HPV vaccine reduces abnormal pap test results

harminka — Mon, 10 Mar 2008 12:22:57 -0500

A significant drop in abnormal Pap test results happened after girls and women were given a vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).

How to detect low abundant lamivudine-resistant mutants?

harminka — Wed, 16 Jan 2008 09:09:51 -0600

Lamivudine is an effective antiviral agent for treatment of patients with chronic hepatitis B and advanced liver diseases.

Most UK citizens susceptible to hepatitis B infection

harminka — Sat, 10 Nov 2007 04:27:15 -0600

The failure of the UK to introduce universal hepatitis B immunisation means that most UK citizens are susceptible to infection, warns an infectious diseases expert in this week’s BMJ.

Researchers find way to fight treacherous hepatitis B

harminka — Tue, 02 Oct 2007 09:51:42 -0500

One in four people who are chronically infected with hepatitis B will die from its impact if untreated, but a team of researchers at the Stanford University School of Medicine has identified the most cost-effective way of fighting this treacherous infection.

Hepatitis B Already Global Epidemic

Dinka — Sat, 08 Sep 2007 07:53:20 -0500

Hepatitis B is caused by a virus that infects the liver, causing disease that can lead to a deadly cancer. The World Health Organization calls hepatitis B a serious global public health problem. Many people who have it, even in the United States, are completely unaware they are infected.

Developing tool to gauge quality of life of hepatitis B patients

harminka — Wed, 11 Jul 2007 12:04:22 -0500

“Am I going to die" I have no future.” “I feel depressed at times, fearful I may not see my children marry or be a grandparent.” Such heart-rending statements from patients with chronic hepatitis B reveal the social and mental impact of this disease, which affects 350 million worldwide.

Hepatitis B drug can compromise HIV treatment

harminka — Thu, 21 Jun 2007 01:04:59 -0500

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.